Binimetinib is an oral, selective MEK1/2 inhibitor that targets the MAPK/ERK signaling pathway, which is often overactive in certain cancers, particularly BRAF V600–mutated melanoma. Developed by Novartis in the early 2010s, it was designed as a targeted therapy to slow tumor growth and improve patient outcomes by tailoring treatment to specific genetic mutations. Clinical trials demonstrated its effectiveness, especially when used in combination with BRAF inhibitors such as encorafenib. In 2018, Binimetinib received regulatory approval for treating metastatic or unresectable melanoma, marking a significant advancement in precision oncology. Since then, it has become an important option in targeted cancer therapy, offering hope for patients with tumors driven by MAPK pathway abnormalities.
